ZELVYSIA™ (sapropterin dihydrochloride)
| Full Name | ZELVYSIA™ (sapropterin dihydrochloride) |
| Drug | sapropterin dihydrochloride |
| Manufacturer | Aucta Pharmaceuticals, Inc |
| Route of Administration | Oral |
| Site of Care | Home |
| Approved Indication | Indicated to reduce blood phenylalanine (Phe) levels in adult and pediatric patients one month of age and older with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin‑ (BH4‑) responsive Phenylketonuria (PKU). Zelvysia is to be used in conjunction with a Phe‑restricted diet. |
| Disease | Phenylketonuria (PKU) |
| Therapeutic Area | Endocrinology, Metabolic Disorder |
| Enrollment Form Link | Enrollment Form |
| Phone Number | (773) 598-6135 |
| Fax Number | (877) 299-8203 |
| Patient Resources | Alliance of PKU Families, flok, and National PKU Alliance |